Phase 2 Study of Fingolimod in Lung Cancers

This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for efficacy analysis where fingolimod 0.5 mg will be taken orally once daily.

Trial Details

NCT ID
NCT06424067
Phase
PHASE2
Sponsor
Medical University of South Carolina
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Fingolimod 0.5 milligram (mg) [Gilenya]
Locations (sample)
  • Charleston, South Carolina, United States|32.77632,-79.93275

Key Eligibility Criteria

  • Voluntary, signed, and dated, Institutional Review Board (IRB) approved consent form in accordance with regulatory and institutional guidelines.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Male or female
  • 18 years of age or older

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →